Biogen's Litifilimab Shows Durable Lupus Skin Benefits at 52 Weeks
New Phase 2 data show Biogen's litifilimab sustained skin disease improvements in cutaneous lupus patients through one year, with rapid onset in switchers.
Biogen Inc. reported 52-week results Thursday from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 study evaluating litifilimab in patients with cutaneous lupus erythematosus, a chronic skin condition associated with lupus. The data, presented at the European Academy of Dermatology and Venereology Congress in Vienna, represent the longest dataset yet published for the drug in this indication.
Participants who received litifilimab throughout the double-blind, placebo-controlled period continued to show clinical improvements in skin disease activity through Week 52, according to the Cambridge, Massachusetts-based company. The findings reinforce earlier results and suggest the treatment's benefits extend well beyond the initial study window.
Read more MIMARU Opens Osaka Namba Apartment Hotel With Sky Garden Suite →
A notable secondary finding involved participants who had been on placebo and switched to litifilimab at Week 24. That group experienced a measurable onset of treatment effect as early as four weeks after switching, suggesting the drug acts quickly once initiated regardless of when therapy begins.
Biogen is positioning litifilimab as a potential first-in-class therapy for cutaneous lupus erythematosus, a condition for which treatment options remain limited. The Phase 3 portion of the AMETHYST study is ongoing, and the one-year Phase 2 dataset is expected to inform the broader regulatory and clinical development path for the drug.
Analysts tracking the lupus pipeline will note that durable efficacy data through a full year, combined with a rapid onset signal, addresses two common barriers to adoption for biologic therapies in dermatology. Continue reading at GlobeNewswire - Industry News on Financial Services.
